PE20211592A1 - Pirazoles como moduladores de la hemoglobina - Google Patents

Pirazoles como moduladores de la hemoglobina

Info

Publication number
PE20211592A1
PE20211592A1 PE2021000762A PE2021000762A PE20211592A1 PE 20211592 A1 PE20211592 A1 PE 20211592A1 PE 2021000762 A PE2021000762 A PE 2021000762A PE 2021000762 A PE2021000762 A PE 2021000762A PE 20211592 A1 PE20211592 A1 PE 20211592A1
Authority
PE
Peru
Prior art keywords
hemoglobin
pirazoles
compounds
pirazol
oxy
Prior art date
Application number
PE2021000762A
Other languages
English (en)
Inventor
Ariamala Gopalsamy
Arjun Venkat Narayanan
Agustin Casimiro-Garcia
Chulho Choi
David Hepworth
David Walter Piotrowski
Hatice Gizem Yayla
Jayasankar Jasti
Lee Richard Roberts
Lyn Howard Jones
Mihir Dineshkumar Parikh
Ming Zhu Chen
Omezia Fadeyi Olugbeminiyi
Jr Ralph Pelton Robinson
Robert Lee Dow
Shawn Cabral
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20211592A1 publication Critical patent/PE20211592A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRAZOL DE FORMULA (I) DONDE X, Y, R2 Y R3 SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: ACIDO 3-{(1S)-1-[(2-AMINO-6,8-DIFLUOROQUINOLIN-3-IL)OXI]ETIL}-4-(1H-PIRAZOL-1-IL)BENZOICO; 6-{(1S)-1-[(2-AMINO-6-FLUOROQUINOLIN-3-IL)OXI]ETIL}-5-(1H-PIRAZOL-1-IL)PIRIDIN-2-OL; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE HEMOGLOBINA (HB) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA HEMOGLOBINA FALCIFORME (HBS) TAL COMO LA ENFERMEDAD DE CELULAS FALCIFORME (SCD).
PE2021000762A 2018-11-29 2019-11-26 Pirazoles como moduladores de la hemoglobina PE20211592A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772815P 2018-11-29 2018-11-29
US201962915784P 2019-10-16 2019-10-16
PCT/IB2019/060171 WO2020109994A1 (en) 2018-11-29 2019-11-26 Pyrazoles as modulators of hemoglobin

Publications (1)

Publication Number Publication Date
PE20211592A1 true PE20211592A1 (es) 2021-08-18

Family

ID=68807213

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000762A PE20211592A1 (es) 2018-11-29 2019-11-26 Pirazoles como moduladores de la hemoglobina

Country Status (22)

Country Link
US (3) US11014908B2 (es)
EP (1) EP3886984A1 (es)
JP (1) JP2022510628A (es)
KR (1) KR20210097161A (es)
CN (1) CN113329789A (es)
AU (1) AU2019387290A1 (es)
BR (1) BR112021009057A2 (es)
CA (1) CA3121139A1 (es)
CO (1) CO2021006924A2 (es)
CR (1) CR20210284A (es)
CU (1) CU20210044A7 (es)
DO (1) DOP2021000103A (es)
EC (1) ECSP21037191A (es)
IL (1) IL283408A (es)
MA (1) MA54283A (es)
MX (1) MX2021006095A (es)
PE (1) PE20211592A1 (es)
PH (1) PH12021551035A1 (es)
SG (1) SG11202104585YA (es)
TW (2) TW202140452A (es)
UY (1) UY38488A (es)
WO (1) WO2020109994A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210284A (es) * 2018-11-29 2021-07-09 Pfizer Pirazoles como modulares de hemoglobina
IL294921A (en) 2020-01-24 2022-09-01 Pfizer Antibodies against E-selectin, preparations and methods of use
CN112079774A (zh) * 2020-10-17 2020-12-15 甘肃天后光学科技有限公司 软性隐形眼镜用蓝光吸收剂、其制备方法及应用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
JP2007176799A (ja) 2005-12-27 2007-07-12 Sankyo Co Ltd 置換ベンゼン化合物を含有する医薬
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2011015524A2 (en) 2009-08-03 2011-02-10 Bayer Cropscience Ag Fungicide heterocycles derivatives
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
JP2013525476A (ja) * 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2963218T3 (es) * 2011-12-28 2024-03-25 Global Blood Therapeutics Inc Productos intermedios para obtener compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular
US20140271591A1 (en) * 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
CN111454200A (zh) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US20160083343A1 (en) 2013-03-15 2016-03-24 Global Blood Therapeutics, Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105209469A (zh) 2013-03-15 2015-12-30 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) * 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9248199B2 (en) * 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
WO2015193506A1 (en) 2014-06-20 2015-12-23 Institut Pasteur Korea Anti-infective compounds
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
US9920072B2 (en) 2014-11-03 2018-03-20 Hoffmann-La Roche Inc. BACE1 inhibitors
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3472150A1 (en) 2016-06-17 2019-04-24 Fronthera U.S. Pharmaceuticals LLC Hemoglobin modifier compounds and uses thereof
CA3158951A1 (en) 2016-08-15 2018-02-22 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
CR20210284A (es) * 2018-11-29 2021-07-09 Pfizer Pirazoles como modulares de hemoglobina

Also Published As

Publication number Publication date
EP3886984A1 (en) 2021-10-06
TW202033513A (zh) 2020-09-16
CU20210044A7 (es) 2022-01-13
KR20210097161A (ko) 2021-08-06
MX2021006095A (es) 2021-07-06
CO2021006924A2 (es) 2021-06-10
MA54283A (fr) 2022-03-09
TWI736037B (zh) 2021-08-11
PH12021551035A1 (en) 2021-12-06
JP2022510628A (ja) 2022-01-27
SG11202104585YA (en) 2021-06-29
TW202140452A (zh) 2021-11-01
DOP2021000103A (es) 2021-07-30
ECSP21037191A (es) 2021-06-30
AU2019387290A1 (en) 2021-05-27
US11014908B2 (en) 2021-05-25
IL283408A (en) 2021-07-29
CA3121139A1 (en) 2020-06-04
US20200172512A1 (en) 2020-06-04
UY38488A (es) 2020-06-30
CR20210284A (es) 2021-07-09
US11702405B2 (en) 2023-07-18
US20230382892A1 (en) 2023-11-30
CN113329789A (zh) 2021-08-31
BR112021009057A2 (pt) 2021-08-10
WO2020109994A1 (en) 2020-06-04
US20220348555A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
PE20211592A1 (es) Pirazoles como moduladores de la hemoglobina
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
PE20120602A1 (es) ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
PE20130009A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PH12014502524A1 (en) Carboxylic acid compounds
NZ609309A (en) Redox drug derivatives
MA37405A1 (fr) Composés hétérocyclyle
BR112013019955A2 (pt) n-[3-(5-amino-3,3a,7,7a-tetra-hidro-1h-2,4-dioxa-6-aza-inden-7-il)-fenil]-amidas como inibidores de bace1 e/ou de bace2
EA201690899A1 (ru) Оксазепины в качестве модуляторов ионных каналов
PE20141056A1 (es) Metodos para el tratamiento de vhc
EA201001508A1 (ru) Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич
MX2012001985A (es) Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina.
EA200901573A1 (ru) Гетероарилзамещенные тиазолы
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
EA201100299A1 (ru) Органические соединения
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
EA201201661A1 (ru) Новые аминопиразолохиназолины
MA30402B1 (fr) Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
BR112014015630A2 (pt) fluorometil-5,6-di-hidro-4h-[1,3]oxazinas
PE20151666A1 (es) Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
EA201792597A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения